Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.43 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.43 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31065210 | 1.00 | PAX8 (0.54) | PAX8LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4062182 | 0.93 | PAX8 (0.54) | PAX8LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4075047 | 0.88 | MAPT (0.53) | PAX8LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4063973 | 0.83 | LMNA (0.55) | PAX8LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL31065219 | 0.83 | LMNA (0.55) | PAX8LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4067165 | 0.81 | MAPT (0.53) | PAX8LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4062720 | 0.80 | CYP3A4 (0.47) | PAX8LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4072975 | 0.79 | ALDH1A1 (0.50) | PAX8LMNASMN1; SMN2RAB9AMAPT | |
| SCHEMBL18840973 | 0.79 | ALDH1A1 (0.48) | LMNANPC1RAB9AHTTL3MBTL1 | |
| SCHEMBL4063854 | 0.78 | MAPT (0.50) | LMNARAB9AHTTMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4686472-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE | Dompé farmaceutici SpA (IT) | 2026-02-04 | — | — | EP | claimed |
| EP-4686469-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF DIABETES-ASSOCIATED COMORBIDITIES | Dompé farmaceutici SpA (IT) | 2026-02-04 | — | — | EP | claimed |
| EP-4678171-A1 | SYSTEMICALLY-ADMINISTERED CXCL8 INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompé farmaceutici SpA (IT) | 2026-01-14 | — | — | EP | claimed |
| EP-4563594-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF TUMORS WITH LOW STROMAL CAV1 LEVELS | Dompe' Farmaceutici SpA (IT) | 2025-06-04 | — | — | EP | claimed |
| EP-4397305-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompe' Farmaceutici S.P.A. (IT) | 2024-07-10 | — | — | EP | claimed |
| US-20240156757-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | DOMPE' FARMACEUTICI SPA (IT) | 2024-05-16 | — | — | US | claimed |
| EP-4301351-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | Dompe' Farmaceutici SpA (IT) | 2024-01-10 | — | — | EP | claimed |
| WO-2022184841-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | DOMPE' FARMACEUTICI SPA (IT) | 2022-09-09 | — | — | WO | claimed |
| EP-4052702-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | Dompé farmaceutici S.p.a. (IT) | 2022-09-07 | — | — | EP | claimed |
| EP-2033955-A1 | Urea derivatives of 1H-pyrazol-4-carboxylic acid with neutrophil chemotaxis inhibiting activity | Universita' Degli Studi Di Genova (IT) | 2009-03-11 | — | — | EP | claimed |
| EP-4686472-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE | Dompé farmaceutici SpA (IT) | 2026-02-04 | — | — | EP | disclosed |
| EP-4686469-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF DIABETES-ASSOCIATED COMORBIDITIES | Dompé farmaceutici SpA (IT) | 2026-02-04 | — | — | EP | disclosed |
| EP-4678171-A1 | SYSTEMICALLY-ADMINISTERED CXCL8 INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompé farmaceutici SpA (IT) | 2026-01-14 | — | — | EP | disclosed |
| EP-4563594-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF TUMORS WITH LOW STROMAL CAV1 LEVELS | Dompe' Farmaceutici SpA (IT) | 2025-06-04 | — | — | EP | disclosed |
| US-20250161248-A1 | Treating Chronic Myelomonocytic Leukemia with CXCL8 Receptor Inhibitors | INSTITUT GUSTAVE ROUSSY (FR) | 2025-05-22 | — | — | US | disclosed |
| US-20240156757-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | DOMPE' FARMACEUTICI SPA (IT) | 2024-05-16 | — | — | US | disclosed |
| EP-4301351-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | Dompe' Farmaceutici SpA (IT) | 2024-01-10 | — | — | EP | disclosed |
| WO-2022184841-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | DOMPE' FARMACEUTICI SPA (IT) | 2022-09-09 | — | — | WO | disclosed |
| EP-4052702-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | Dompé farmaceutici S.p.a. (IT) | 2022-09-07 | — | — | EP | disclosed |
| EP-2033955-A1 | Urea derivatives of 1H-pyrazol-4-carboxylic acid with neutrophil chemotaxis inhibiting activity | Universita' Degli Studi Di Genova (IT) | 2009-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161248-A1 | Treating Chronic Myelomonocytic Leukemia with CXCL8 Receptor Inhibitors | CXCL8, CCR8, CSF3R | PAX8 67/4885LMNA 4692/4885SMN1; SMN2 3561/4885 |
| US-20240156757-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | CXCL8, CCR8, CXCL10 | PAX8 110/4885LMNA 4656/4885SMN1; SMN2 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.